8,721 Shares in BioNTech SE (NASDAQ:BNTX) Bought by Bellevue Group AG

Bellevue Group AG bought a new position in BioNTech SE (NASDAQ:BNTX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 8,721 shares of the company’s stock, valued at approximately $1,036,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in shares of BioNTech by 86.9% in the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after purchasing an additional 238 shares during the period. EverSource Wealth Advisors LLC increased its position in BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after buying an additional 252 shares during the period. Planning Capital Management Corp lifted its holdings in shares of BioNTech by 45,000.0% during the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after buying an additional 450 shares during the last quarter. Blue Trust Inc. boosted its position in shares of BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares during the period. Finally, Daiwa Securities Group Inc. grew its stake in shares of BioNTech by 430.3% in the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock worth $155,000 after acquiring an additional 1,562 shares during the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on BNTX shares. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the company from $90.00 to $137.00 in a research note on Friday, November 8th. Canaccord Genuity Group increased their target price on shares of BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research note on Wednesday. HC Wainwright restated a “buy” rating and set a $150.00 price target on shares of BioNTech in a research note on Monday, November 18th. Bank of America upped their price target on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 16th. Finally, Berenberg Bank assumed coverage on BioNTech in a report on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective on the stock. Four research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $138.67.

BioNTech Trading Down 1.9 %

Shares of BioNTech stock opened at $118.39 on Friday. The stock has a market capitalization of $28.38 billion, a P/E ratio of -56.38 and a beta of 0.26. BioNTech SE has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a 50-day simple moving average of $113.81 and a 200 day simple moving average of $98.68. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company’s quarterly revenue was up 38.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.73 EPS. Research analysts expect that BioNTech SE will post -3.68 earnings per share for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.